Published in J Acquir Immune Defic Syndr on September 01, 2014
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients | NCT02344680
Elevated AST-to-platelet ratio index is associated with increased all-cause mortality among HIV-infected adults in Zambia. Liver Int (2015) 1.68
Observational research on NCDs in HIV-positive populations: conceptual and methodological considerations. J Acquir Immune Defic Syndr (2014) 0.87
Trends in upper gastrointestinal diagnosis over four decades in Lusaka, Zambia: a retrospective analysis of endoscopic findings. BMC Gastroenterol (2015) 0.78
Prevalence of and risk for gastrointestinal bleeding and peptic ulcerative disorders in a cohort of HIV patients from a U.S. healthcare claims database. PLoS One (2017) 0.75
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet (2007) 11.06
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature (2012) 10.74
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med (2006) 9.21
Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med (2008) 7.71
Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS (2006) 7.08
Child undernutrition, tropical enteropathy, toilets, and handwashing. Lancet (2009) 4.25
Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr (2008) 3.44
Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol (2005) 3.18
HIV infection and the risk of cancers with and without a known infectious cause. AIDS (2009) 3.13
Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis (2009) 2.78
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Enteropathies in the developing world: neglected effects on global health. Am J Trop Med Hyg (2012) 2.27
Association between weight gain and clinical outcomes among malnourished adults initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr (2010) 2.21
High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther (2011) 2.20
The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol (2007) 2.19
Probiotics and prebiotics for severe acute malnutrition (PRONUT study): a double-blind efficacy randomised controlled trial in Malawi. Lancet (2009) 2.15
Case management of HIV-infected severely malnourished children: challenges in the area of highest prevalence. Lancet (2008) 2.08
Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis (2008) 2.06
Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr (2009) 1.98
Mortality and associated factors after initiation of pediatric antiretroviral treatment in the Democratic Republic of the Congo. Pediatr Infect Dis J (2009) 1.91
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis (2002) 1.87
Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology (2009) 1.84
HIV prevalence and mortality among children undergoing treatment for severe acute malnutrition in sub-Saharan Africa: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg (2008) 1.81
The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol (2010) 1.79
Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis (2000) 1.74
Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort. HIV Med (2008) 1.74
Responses of small intestinal architecture and function over time to environmental factors in a tropical population. Am J Trop Med Hyg (2004) 1.54
The impoverished gut--a triple burden of diarrhoea, stunting and chronic disease. Nat Rev Gastroenterol Hepatol (2012) 1.53
Primary esophageal carcinoma in the era of highly active antiretroviral therapy. Arch Intern Med (2010) 1.52
Cancer incidence in New York State acquired immunodeficiency syndrome patients. Am J Epidemiol (2001) 1.51
Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr (2006) 1.49
Diagnosis of primary cancer of the liver. Br Med J (1971) 1.45
Micronutrient supplementation in children and adults with HIV infection. Cochrane Database Syst Rev (2010) 1.43
Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 1.40
Geography of intestinal permeability and absorption. Gut (1999) 1.26
The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. Afr Health Sci (2008) 1.25
Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr (2003) 1.21
Favourable one-year ART outcomes in adult Malawians with hepatitis B and C co-infection. J Infect (2010) 1.18
Gastrointestinal pathology in the University Teaching Hospital, Lusaka, Zambia: review of endoscopic and pathology records. Trans R Soc Trop Med Hyg (2007) 1.18
Clinical outcomes of severe malnutrition in a high tuberculosis and HIV setting. Arch Dis Child (2011) 1.16
Challenges in the Management of HIV-Infected Malnourished Children in Sub-Saharan Africa. AIDS Res Treat (2012) 1.14
The chest radiograph in primary liver cancer: an analysis of 449 cases. S Afr Med J (1976) 1.13
Nutritional interventions for reducing morbidity and mortality in people with HIV. Cochrane Database Syst Rev (2013) 1.10
Who's talking? Communication between health providers and HIV-infected adults related to herbal medicine for AIDS treatment in western Uganda. Soc Sci Med (2008) 1.10
Variability of growth in children starting antiretroviral treatment in southern Africa. Pediatrics (2012) 1.08
Gastric cancer in Africa: what do we know about incidence and risk factors? Trans R Soc Trop Med Hyg (2011) 1.08
The impact of malnutrition in survival of HIV infected children after initiation of antiretroviral treatment (ART). Ethiop Med J (2010) 1.05
Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. Am J Clin Nutr (2008) 1.04
Helicobacter pylori infection in an urban African population. J Clin Microbiol (2001) 1.03
Association of gastric hypoacidity with opportunistic enteric infections in patients with AIDS. J Infect Dis (1992) 1.02
Prompt initiation of ART With therapeutic food is associated with improved outcomes in HIV-infected Malawian children with malnutrition. J Acquir Immune Defic Syndr (2012) 1.02
Hepatocellular carcinoma in developing countries: Prevention, diagnosis and treatment. World J Hepatol (2012) 1.01
Human immunodeficiency virus and the gastrointestinal immune system: does highly active antiretroviral therapy restore gut immunity? Mucosal Immunol (2012) 1.01
Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda. Int J STD AIDS (2010) 1.00
Effect of nutritional factors on adherence to antiretroviral therapy among HIV-infected adults: a case control study in Northern Ethiopia. BMC Infect Dis (2013) 1.00
Severe malnutrition and metabolic complications of HIV-infected children in the antiretroviral era: clinical care and management in resource-limited settings. Am J Clin Nutr (2011) 0.99
Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study. Clin Infect Dis (2012) 0.98
Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor {gamma} and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy. Mol Endocrinol (2007) 0.97
Retracted Increased risk of stomach and esophageal malignancies in people with AIDS. Gastroenterology (2012) 0.96
The influence of nutritional status on the response to HAART in HIV-infected children in South Africa. Pediatr Infect Dis J (2010) 0.95
Alcohol Consumption, Progression of Disease and Other Comorbidities, and Responses to Antiretroviral Medication in People Living with HIV. AIDS Res Treat (2012) 0.94
Micronutrients: current issues for HIV care providers. AIDS (2005) 0.94
Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. BMC Gastroenterol (2010) 0.93
Traditional herbal medicine use associated with liver fibrosis in rural Rakai, Uganda. PLoS One (2012) 0.92
Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999). J Acquir Immune Defic Syndr (2006) 0.92
Self-reported dietary intake and appetite predict early treatment outcome among low-BMI adults initiating HIV treatment in sub-Saharan Africa. Public Health Nutr (2012) 0.92
Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease. Obes Surg (2010) 0.90
Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. BMC Public Health (2010) 0.89
Gastric adenocarcinoma in Zambia: a case-control study of HIV, lifestyle risk factors, and biomarkers of pathogenesis. S Afr Med J (2013) 0.87
Nutrition, intestinal defence and the microbiome. Proc Nutr Soc (2010) 0.87
Ready to Use Therapeutic Foods (RUTF) improves undernutrition among ART-treated, HIV-positive children in Dar es Salaam, Tanzania. Nutr J (2012) 0.85
Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV. PLoS One (2013) 0.83
Challenges in the detection, prevention, and treatment of HIV-associated malignancies in low- and middle-income countries in Africa. J Acquir Immune Defic Syndr (2014) 0.80
Prevalence and characteristics associated with malnutrition at hospitalization among patients with acquired immunodeficiency syndrome in Brazil. PLoS One (2012) 0.79
Changes in parietal cell structure and function in HIV disease. Dig Dis Sci (1996) 0.79
The contribution of alcohol to chronic liver disease in patients from South-west Nigeria. Niger J Clin Pract (2010) 0.78
The effect of multiple micronutrient supplementation on mortality and morbidity of HIV-infected adults: a meta-analysis of randomized controlled trials. J Nutr Sci Vitaminol (Tokyo) (2012) 0.78
Efficacy and safety of zinc supplementation for adults, children and pregnant women with HIV infection: systematic review. Trop Med Int Health (2011) 0.76
Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet (2006) 8.32
Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis (2002) 5.34
A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell (2012) 4.49
A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe (2009) 4.24
Hepatic portal venous gas: the ABCs of management. Arch Surg (2009) 3.76
Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest (2003) 3.40
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology (2004) 2.91
CD8 epitope escape and reversion in acute HCV infection. J Exp Med (2004) 2.77
Case records of the Massachusetts General Hospital. Case 23-2005. A 57-year-old man with a mass in the liver. N Engl J Med (2005) 2.67
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology (2008) 2.45
The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int (2009) 2.33
Development of an accurate index for predicting outcomes of patients with acute liver failure. Gastroenterology (2012) 2.26
Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology (2009) 2.13
Viral sequence evolution in acute hepatitis C virus infection. J Virol (2007) 2.13
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13
A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology (2011) 2.08
Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol (2002) 2.03
Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood (2008) 2.01
High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome. J Virol (2007) 2.01
Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol (2002) 1.98
Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA (2008) 1.94
Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J Virol (2006) 1.87
Hepatitis C virus expression suppresses interferon signaling by degrading STAT1. Gastroenterology (2005) 1.87
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology (2009) 1.80
Coinfection with HIV-1 and HCV--a one-two punch. Gastroenterology (2009) 1.78
Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl (2005) 1.76
Non-high-density lipoprotein cholesterol as a biomarker for nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2012) 1.74
Influence of high body mass index on outcome in acute liver failure. Clin Gastroenterol Hepatol (2006) 1.74
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology (2006) 1.73
DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol (2008) 1.71
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol (2007) 1.71
Spontaneous resolution of chronic hepatitis C virus disease after withdrawal of immunosuppression. Gastroenterology (2003) 1.68
Breast-feeding, antiretroviral prophylaxis, and HIV. N Engl J Med (2008) 1.66
IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol (2010) 1.64
GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype. J Infect Dis (2006) 1.64
HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology (2008) 1.60
Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol (2005) 1.59
Gc-globulin and prognosis in acute liver failure. Liver Transpl (2005) 1.59
Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol (2005) 1.54
The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood (2004) 1.53
Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol (2002) 1.52
Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology (2010) 1.51
Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology (2010) 1.51
Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance. Liver Transpl (2008) 1.50
Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis (2009) 1.49
Management strategies using pharmacogenomics in patients with severe HCV-1b infection: a decision analysis. Hepatology (2002) 1.47
Kinetic differences in the induction of interferon stimulated genes by interferon-α and interleukin 28B are altered by infection with hepatitis C virus. Hepatology (2014) 1.46
Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution. Hepatology (2007) 1.44
Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology (2005) 1.44
Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med (2012) 1.43
A functional genomic screen reveals novel host genes that mediate interferon-alpha's effects against hepatitis C virus. J Hepatol (2011) 1.41
A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication. Gastroenterology (2006) 1.40
Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol (2002) 1.40
Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med (2006) 1.36
Interaction of NK inhibitory receptor genes with HLA-C and MHC class II alleles in Hepatitis C virus infection outcome. Mol Immunol (2008) 1.36
Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer (2007) 1.30
Serum apoptosis markers in acute liver failure: a pilot study. Clin Gastroenterol Hepatol (2007) 1.29
Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology (2005) 1.26
Implementation of WHO guidelines on management of severe malnutrition in hospitals in Africa. Bull World Health Organ (2003) 1.25
HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB. J Biol Chem (2010) 1.24
Anti-hepatitis C virus drugs in development. Gastroenterology (2012) 1.23
Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int (2010) 1.22
Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation (2004) 1.22
Lower respiratory tract infections associated with influenza A and B viruses in an area with a high prevalence of pediatric human immunodeficiency type 1 infection. Pediatr Infect Dis J (2002) 1.22
Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr Infect Dis J (2002) 1.19
Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol (2004) 1.18
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology (2009) 1.18
Clinical outcomes of severe malnutrition in a high tuberculosis and HIV setting. Arch Dis Child (2011) 1.16
Detection of hepatitis C virus (HCV) in serum and peripheral-blood mononuclear cells from HCV-monoinfected and HIV/HCV-coinfected persons. J Infect Dis (2005) 1.14
Hepatitis C virus (HCV) diversity in HIV-HCV-coinfected subjects initiating highly active antiretroviral therapy. J Infect Dis (2004) 1.14
Pathogenesis of accelerated fibrosis in HIV/HCV co-infection. J Infect Dis (2013) 1.14
IgG4-associated cholangitis: a comparative histological and immunophenotypic study with primary sclerosing cholangitis on liver biopsy material. Mod Pathol (2009) 1.11
Acute liver failure: mechanisms of hepatocyte injury and regeneration. Semin Liver Dis (2008) 1.09
Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol (2006) 1.08
De novo autoimmune hepatitis during immune reconstitution in an HIV-infected patient receiving highly active antiretroviral therapy. Clin Infect Dis (2008) 1.07
HCV and host lipids: an intimate connection. Semin Liver Dis (2013) 1.06
Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling. J Virol (2012) 1.06
Anti-inflammatory treatment for carditis in acute rheumatic fever. Cochrane Database Syst Rev (2012) 1.06
Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol (2008) 1.06
A genetic screen identifies interferon-α effector genes required to suppress hepatitis C virus replication. Gastroenterology (2013) 1.06
Treatment of recurrent allograft dysfunction with intravenous hematin after liver transplantation for erythropoietic protoporphyria. Transplantation (2002) 1.05
An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One (2011) 1.04
Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology (2007) 1.03
Novel therapies for hepatitis C: insights from the structure of the virus. Annu Rev Med (2011) 1.03
Protein kinase R is increased and is functional in hepatitis C virus-related hepatocellular carcinoma. Am J Gastroenterol (2003) 1.03
Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study. Liver Transpl (2004) 1.02
Treatment failure in hepatitis C: mechanisms of non-response. J Hepatol (2008) 1.02
Nutritional status of Malawian adults on antiretroviral therapy 1 year after supplementary feeding in the first 3 months of therapy. Trop Med Int Health (2009) 1.01
Reassuring Birth Outcomes With Tenofovir/Emtricitabine/Efavirenz Used for Prevention of Mother-to-Child Transmission of HIV in Botswana. J Acquir Immune Defic Syndr (2016) 1.00
Hepatitis C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis. Hepatology (2005) 0.99
Intrahepatic cytokine expression is downregulated during HCV/HIV co-infection. J Med Virol (2006) 0.99
Suppressor of cytokine signaling 3 suppresses hepatitis C virus replication in an mTOR-dependent manner. J Virol (2010) 0.99
High antibody level: an accurate serologic marker of viremia in asymptomatic people with hepatitis C infection. Transfusion (2010) 0.99
Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection. J Hepatol (2009) 0.98
Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection. Blood (2007) 0.98